| [1] |
Keri KC, Blumenthal S, Kulkarni V, et al. Primary membranous nephropathy: comprehensive review and historical perspective [J]. Postgrad Med J, 2019, 95(1119): 23-31.
|
| [2] |
Hou JH, Zhu HX, Zhou ML, et al. Changes in the spectrum of kidney diseases: an analysis of 40，759 biopsy-proven cases from 2003 to 2014 in China [J]. Kidney Dis (Basel), 2018, 4(1): 10-19.
|
| [3] |
Asim M, Akhtar M. Epidemiology, impact, and management strategies of anti-glomerular basement membrane disease [J]. Int J Nephrol Renovasc Dis, 2022, 15: 129-138.
|
| [4] |
Wu L, Lai J, Ling Y, et al. A review of the current practice of diagnosis and treatment of idiopathic membranous nephropathy in China [J]. Med Sci Monit, 2021, 27: e930097.
|
| [5] |
Hellmark T, Segelmark M. Diagnosis and classification of Goodpasture′s disease (anti-GBM) [J]. J Autoimmun, 2014, 48-49: 108-112.
|
| [6] |
Klassen J, Elwood C, Grossberg AL, et al. Evolution of membranous nephropathy into anti-glomerular-basement-membrane glomerulonephritis [J]. N Engl J Med, 1974, 290(24): 1340-1344.
|
| [7] |
Basford AW, Lewis J, Dwyer JP, et al. Membranous nephropathy with crescents [J]. J Am Soc Nephrol, 2011, 22(10): 1804-1808.
|
| [8] |
Jia XY, Hu SY, Chen JL, et al. The clinical and immunological features of patients with combined anti-glomerular basement membrane disease and membranous nephropathy [J]. Kidney Int, 2014, 85(4): 945-952.
|
| [9] |
崔昭，赵明辉. 抗肾小球基底膜病及其免疫发病机制的研究进展[J]. 郑州大学学报(医学版), 2008, 43(1): 10-13.
|
| [10] |
Patel D, Nivera N, Tunkel AR. Anti-glomerular basement membrane disease superimposed on membranous nephropathy: a case report and review of the literature [J]. J Med Case Rep, 2010, 4: 237.
|
| [11] |
Cui Z, Zhao MH, Wang SX, et al. Concurrent antiglomerular basement membrane disease and immune complex glomerulonephritis [J]. Ren Fail, 2006, 28(1): 7-14.
|
| [12] |
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases [J]. Kidney Int, 2021, 100(4S): S1-S276.
|
| [13] |
Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab) [J]. Ann Rheum Dis, 2002, 61(10): 922-924.
|
| [14] |
Bandak G, Jones BA, Li J, et al. Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy [J]. Clin Kidney J, 2014, 7(1): 53-56.
|